Drug intelligence / Profile preview

IVL2003

Development stage: Preclinical
Lead developer: Inventage Lab
Modality: Peptides
Administration: Subcutaneous

Overview

IVL2003 is a long-acting injectable peptide therapeutic being developed by Inventage Lab, in collaboration with Virbac, for veterinary applications. The drug is designed for chemical castration and temporary contraception in animals by modulating the gonadotropin-releasing hormone (GnRH) receptor. It utilizes Inventage Lab's proprietary microsphere-based drug delivery platform to provide sustained release of the active peptide, offering a non-surgical alternative to traditional castration. As of the latest pipeline updates, IVL2003 is in the preclinical stage of development.

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on IVL2003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVL2003.

Explore the full profile